TSX up after index logs fresh record high close
ORANGE, Calif. - Alignment Healthcare, Inc. (NASDAQ:ALHC), a Medicare Advantage provider with a market capitalization of $3.14 billion and impressive year-to-date returns of 41%, announced Monday that Matt Eyles will join the company as executive vice president of government and business strategy, effective Sept. 29.
In this newly created position, Eyles will report directly to founder and CEO John Kao. His responsibilities will include enhancing the company’s engagement in healthcare policy at federal and state levels, leading business planning to anticipate industry changes, and developing new initiatives aligned with enterprise priorities. According to InvestingPro data, the company has demonstrated strong momentum with a 49.46% revenue growth in the last twelve months, suggesting the timing of this strategic hire aligns with the company’s expansion phase.
Eyles previously served as president and CEO of AHIP, the national association representing health insurance providers. During his five-year tenure, he led efforts to expand access to affordable healthcare coverage and revitalized the organization’s advocacy and operations. Modern Healthcare named him one of the 100 Most Influential People in Healthcare for five consecutive years from 2018 to 2022.
"With Alignment’s growing influence and impact, Matt’s appointment comes at exactly the right time," said Kao in the press release.
Prior to AHIP, Eyles held executive roles at Avalere Health, Coventry Health Care/Aetna and Wyeth/Pfizer, accumulating more than 30 years of healthcare experience across private and public sectors.
Alignment Healthcare provides Medicare Advantage plans and operates with a focus on senior care. The company partners with local healthcare providers to deliver coordinated care through its proprietary technology platform AVA.
The announcement comes as the Medicare Advantage provider continues to expand its national footprint in the competitive senior healthcare market. InvestingPro analysis indicates the company maintains a GOOD overall financial health score, with analysts projecting profitability this year. For detailed insights and additional ProTips on ALHC’s growth trajectory, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Alignment Healthcare reported its second-quarter 2025 earnings, which significantly surpassed expectations. The company achieved an earnings per share (EPS) of $0.07, far exceeding the forecasted -$0.07. Revenue for the quarter reached $1 billion, outperforming the anticipated $960.51 million, highlighting strong business growth. Following these results, Barclays upgraded Alignment Healthcare’s stock rating from Underweight to Equalweight, increasing the price target to $13.00 from $9.00. This upgrade was attributed to the company’s solid earnings report, with revenue 6% above forecasts and EBITDA $32 million higher than expected. Additionally, KeyBanc upgraded Alignment Healthcare from Sector Weight to Overweight, setting a price target of $21.00. KeyBanc noted that the company is improving hospital utilization and reinvesting savings into member benefits. These developments indicate a positive outlook from analysts regarding Alignment Healthcare’s growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.